Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026)
Johnson & Johnson (JNJ) posted Interest Coverage Ratio of 2.04 for Q2 2026, up 12.21% sequentially from 1.82 in Q1 2026, and down 20.19% YoY from 2.56 in Q2 2025.
Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Interest Coverage Ratio for 18 years, with the latest figure at 2.04 in Q2 2026.
- Quarterly Interest Coverage Ratio fell 20.19% year-over-year to 2.04 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 7.44 (down 9.87% YoY) and the FY2025 annual result came in at 4.83, down 49.48% from the prior year.
- Interest Coverage Ratio rose to 2.04 in Q2 2026 per JNJ's latest filing, from 1.82 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 71.7 in Q1 2023 and troughed at 11.87 in Q4 2023.
- A 5-year average of 5.02 and a median of 2.5 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio slumped 116.56% in 2023, then jumped 142.14% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 1.89 in 2022, then slumped by 727.44% to 11.87 in 2023, then grew by 9.79% to 10.71 in 2024, then surged by 142.14% to 4.51 in 2025, then plunged by 54.81% to 2.04 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 2.04, 1.82, and 4.51 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.32 Bn | 632.56 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 470.11 Bn | 463.54 Bn | 12.70 Bn | - |
| 3 | Merck | 376.14 Bn | 369.00 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.26 Bn | 295.57 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 257.39 Bn | 252.49 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 236.59 Bn | 222.60 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 181.91 Bn | 178.73 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 159.26 Bn | 147.57 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | -2.64 |
| 10 | Sanofi | 55.11 Bn | 47.73 Bn | 10.79 Bn | -50.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 2.04 |
| Mar 29, 2026 | 1.82 |
| Dec 28, 2025 | 4.51 |
| Sep 28, 2025 | 2.81 |
| Jun 29, 2025 | 2.56 |
| Mar 30, 2025 | 2.81 |
| Dec 29, 2024 | -10.71 |
| Sep 29, 2024 | 2.52 |
| Jun 30, 2024 | 3.24 |
| Mar 31, 2024 | 3.69 |
| Dec 31, 2023 | -11.87 |
| Oct 1, 2023 | 2.50 |
| Jul 2, 2023 | 2.24 |
| Apr 2, 2023 | 2.20 |
| Jan 1, 2023 | 71.70 |
| Oct 2, 2022 | 1.89 |
| Apr 3, 2022 | 1.45 |
| Oct 3, 2021 | 1.84 |
| Jul 4, 2021 | 1.72 |
| Apr 4, 2021 | 1.61 |